Targeting immunosuppressive adenosine in cancer

Nature Reviews Cancer 17, 709 (2017). doi:10.1038/nrc.2017.86 Authors: Dipti Vijayan, Arabella Young, Michele W.L. Teng & Mark J. Smyth Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1 (PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a considerable proportion of patients remain unresponsive to these treatments (known as innate resistance). In addition, one-third of patients relapse
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research